Search clinical trials for: Olodaterol (BI1744)

Total 93 results

Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Boehringer Ingelheim

Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Germany, Hungary
Boehringer Ingelheim

Completed

A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Germany, Netherlands, Norway
Boehringer Ingelheim

Completed

12 / 48 Week Pivotal PFT vs PBO in COPD I

Pulmonary Disease, Chronic Obstructive

United States, Australia, China, Germany, New Zealand, Taiwan
Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma

Asthma

Canada
Boehringer Ingelheim

Completed

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

12 / 48 wk Pivotal PFT vs PBO in COPD II

Pulmonary Disease, Chronic Obstructive

United States, China, Germany, Taiwan
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Asthma

United States, Canada, France, Germany
Boehringer Ingelheim

Completed

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

Pulmonary Disease, Chronic Obstructive

Austria, Germany, Canada, United States, Poland, Belgium, Portugal, United Kingdom, Australia, Denmark, New Zealand
Boehringer Ingelheim

Completed

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

Asthma

United States, Austria, Germany, Hungary, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, Romania, Russian Federation, South Africa, Spain, Sweden, Thailand
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I

Pulmonary Disease, Chronic Obstructive

Argentina, Brazil, Canada, Croatia, Czech Republic, Denmark, Finland, Germany, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Norway, Philippines, South Africa, Spain, Sweden, Thailand, Ukraine
Boehringer Ingelheim

Completed

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Canada, Finland, France, Germany, Hungary, Italy, Spain, United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Denmark, Germany, Hungary, Netherlands
Boehringer Ingelheim

Completed

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Bulgaria, Canada, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Guatemala, Hungary, India, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian... and more
Boehringer Ingelheim

Completed

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Austria, Canada, Germany, Netherlands, Russian Federation, Sweden
Boehringer Ingelheim

Completed

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Australia, Austria, Belgium, Canada, Chile, Germany, Italy, New Zealand
Boehringer Ingelheim

Completed

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Norway, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, United Kingdom
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Withdrawn

Olodaterol Bridging Study in Asthma

Asthma

France
Boehringer Ingelheim

Completed

A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.

Pulmonary Disease, Chronic Obstructive

Japan
University of Dundee

Completed

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (MAN05)

Asthma

United Kingdom
Fraunhofer-Institute of Toxicology and Experimental...
Boehringer Ingelheim

Completed

Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects

Chronic Obstructive Pulmonary Disease

Germany
Boehringer Ingelheim

Completed

Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients

Pulmonary Disease, Chronic Obstructive

Japan
Yonsei University

Not yet recruiting

Effects of Tiotropium/Olodaterol on Cardio-pulmonary Exercise Capacity in Patients With Hyperinflated Chronic Obstructive Pulmonary Disease [ACHIEVE]

Chronic Obstructive Pulmonary Disease

Korea, Republic of
Boehringer Ingelheim

Completed

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

Pulmonary Disease, Chronic Obstructive

Taiwan
Boehringer Ingelheim

Completed

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

Pulmonary Disease, Chronic Obstructive

United States
Ionis Pharmaceuticals, Inc.

Active, not recruiting

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Hereditary Angioedema

Netherlands, United States
Boehringer Ingelheim

Completed

A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

Pulmonary Disease, Chronic Obstructive

United States, Germany
Boehringer Ingelheim

Completed

Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, South Africa, Spain, United Kingdom
Boehringer Ingelheim

Completed

Japan Long-term Safety for Tiotropium Plus Olodaterol

Pulmonary Disease, Chronic Obstructive

Japan
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Puerto Rico, Belgium, Bulgaria, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Turkey, United Kingdom
Boehringer Ingelheim

Completed

Early Intervention Efficacy in COPD

Pulmonary Disease, Chronic Obstructive

Japan
Verona Pharma plc

Completed

Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD

COPD

United States, United Kingdom
Boehringer Ingelheim

Completed

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

Pulmonary Disease, Chronic Obstructive

Germany

3

Subscribe